11-year-old Indian origin boy has turned the first patient to receive a pioneering new cancer therapy by the UK’s state-funded National Health Service in London.
Yuvan Thakkar suffers from relapsed acute lymphoblastic leukaemia (ALL) and received the ground-breaking treatment known as Kymriah – a type of immunotherapy called CAR-T therapy, which modifies a patient’s immune system cells, known as T cells, to attack the cancer cells.
Though the treatment has taken place, Thakkar has some time to go before the results are fully known.
“I really hope I get better soon so I can visit Lego House in Denmark. I love Lego and am building a big model Bugatti while I’m in hospital,” said Thakkar in a statement released by the hospital.
Diagnosed with leukaemia in 2014, Thakkar’s condition relapsed even after he underwent a treatment for bone marrow transplant.
The new therapy is the last hope that Thakkar’s parents are looking forward to reap positive results on their son. The treatment has been tested in clinical trials in the US where it has been shown that approximately 50-62 per cent of patients survive without leukaemia for 12 months or more.
“This new therapy is our last hope. It means a rebirth to us if this treatment works and we hope it really does. We are so glad that we at least have this new option now,” said the anxious parents.
The CAR-T therapy was only available to patients as part of research trials but today a tie up between NHS England and the manufacturer, the therapy is being offered to eligible NHS patients with relapsed acute lymphoblastic leukaemia (ALL).